Education
About Us
Working with TipRanks
Follow Us
EyePoint Pharmaceuticals Inc (EYPT)
NASDAQ:EYPT
EYPT Stock Chart & Stats
$13.68
$0.01(0.11%)
At close: 4:00 PM EST
$13.68
$0.01(0.11%)
Day’s Range― - ―
52-Week Range$3.91 - $14.91
Previous CloseN/A
Volume354.62K
Average Volume (3M)1.50M
Market Cap
$1.13B
Enterprise Value$818.43M
Total Cash (Recent Filing)$204.02M
Total Debt (Recent Filing)$21.30M
Price to Earnings (P/E)―
Beta1.73
Next Earnings
Mar 05, 2026EPS Estimate
-0.75Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.85
Shares Outstanding82,787,220
10 Day Avg. Volume1,250,761
30 Day Avg. Volume1,499,976
Financial Highlights & Ratios
PEG Ratio-0.12
Price to Book (P/B)1.25
Price to Sales (P/S)9.69
P/FCF Ratio-3.22
Enterprise Value/Market Cap0.72
Enterprise Value/Revenue19.33
Enterprise Value/Gross Profit20.55
Enterprise Value/Ebitda-3.90
Forecast
1Y Price Target
$31.60Price Target Upside130.99% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trials ProgressThe independent Data Safety Monitoring Committee (DSMC) recommended that both the LUGANO and LUCIA trials continue as planned without modifications to the protocol.
Financial PositionThe cash position is strong, with a runway projected into late 2027.
Regulatory Path And Market PositionEYPT has pursued a well-established regulatory path for wet AMD approval, which is seen as a strategic advantage.
Bears Say
EYPT FAQ
What was EyePoint Pharmaceuticals Inc’s price range in the past 12 months?
EyePoint Pharmaceuticals Inc lowest stock price was $3.91 and its highest was $14.91 in the past 12 months.
What is EyePoint Pharmaceuticals Inc’s market cap?
EyePoint Pharmaceuticals Inc’s market cap is $1.13B.
When is EyePoint Pharmaceuticals Inc’s upcoming earnings report date?
EyePoint Pharmaceuticals Inc’s upcoming earnings report date is Mar 05, 2026 which is in 101 days.
How were EyePoint Pharmaceuticals Inc’s earnings last quarter?
EyePoint Pharmaceuticals Inc released its earnings results on Nov 05, 2025. The company reported -$0.85 earnings per share for the quarter, missing the consensus estimate of -$0.769 by -$0.081.
Is EyePoint Pharmaceuticals Inc overvalued?
According to Wall Street analysts EyePoint Pharmaceuticals Inc’s price is currently Undervalued.
Does EyePoint Pharmaceuticals Inc pay dividends?
EyePoint Pharmaceuticals Inc does not currently pay dividends.
What is EyePoint Pharmaceuticals Inc’s EPS estimate?
EyePoint Pharmaceuticals Inc’s EPS estimate is -0.75.
How many shares outstanding does EyePoint Pharmaceuticals Inc have?
EyePoint Pharmaceuticals Inc has 82,787,220 shares outstanding.
What happened to EyePoint Pharmaceuticals Inc’s price movement after its last earnings report?
EyePoint Pharmaceuticals Inc reported an EPS of -$0.85 in its last earnings report, missing expectations of -$0.769. Following the earnings report the stock price went down -11.057%.
Which hedge fund is a major shareholder of EyePoint Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in EYPT
EyePoint Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$31.60 (130.99% Upside)
$31.60 (130.99% Upside)
Blogger Sentiment
Bullish
EYPT Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 445.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.3%
Last 30 Days ▲ 5.0%
Last 30 Days ▲ 5.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
63.83%
12-Months-Change
Fundamentals
Return on Equity
-98.23%
Trailing 12-Months
Asset Growth
-16.36%
Trailing 12-Months
Company Description
EyePoint Pharmaceuticals Inc
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.
EYPT Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
EyePoint demonstrated strong clinical progress with successful trial enrollments and maintained a robust financial position to support future operations. However, the company faced challenges with decreased revenue and increased operating expenses leading to a higher net loss. Despite financial setbacks, the strategic advancements in clinical programs and regulatory alignments position EyePoint for continued growth and potential market leadership.View all EYPT earnings summariesEYPT Stock 12 Month Forecast
Average Price Target
$31.60
▲(130.99% Upside)
Technical Analysis
Urogen Pharma
―
Meiragtx Holdings
―
Stoke Therapeutics
―
Tango Therapeutics
―
Pharming Group
―
Ownership Overview
0.75% Insiders
15.00% Mutual Funds
36.75% Other Institutional Investors
38.65% Public Companies and
Individual Investors